Pre-market hot trades in US stocks: Forum Markets down 8.61% in pre-market; Fold up 8.33% in pre-market

Pre-market Hot Trades in US Stocks Forum Markets is down 8.61% in pre-market trading. Based on recent key news: On April 17, Forum Markets restarted its stock repurchase program and established an independent special committee to evaluate proposals to maximize shareholder value. This move may lead to repurchase volumes exceeding safe harbor limits, driving stock price volatility. Source: SEC announcement On April 17, Forum Markets announced plans to enhance value by tokenizing real-world assets. This initiative aims to revolutionize capital markets, expand investor participation, and improve market efficiency. Source: Company announcement On April 17, Forum Markets' technical sentiment signals indicated a strong sell, with the market holding a pessimistic view on its future performance, putting pressure on the stock price. Source: TipRanks report on increased volatility in the digital asset market, caution advised for investors. Fold is up 8.33% in pre-market trading, with no significant news recently. Trading is active, with clear capital flows; considering sector and industry trends, the stock shows notable volatility, with specific reasons needing further observation. Top Gainers in Pre-market US Stocks Psyence Biomedical is up 91.18% in pre-market trading. Based on recent news: On April 17, Psyence Biomedical announced its pharmaceutical-grade psychedelic drug NPX-5 is entering clinical trials. The company's CEO stated that this expansion marks a significant advancement in clinical infrastructure, supporting ongoing patient dosing. This news drove the stock price up by 69.85%. On April 18, U.S. President Trump signed an executive order to expedite research and approval processes for psychedelic therapies, focusing on drugs like ibogaine. This move aims to assist veterans suffering from severe mental illnesses, further boosting the stock price. On April 19, Psyence Biomedical's API development division received federal licensing to support global distribution and clinical projects. The company recently implemented a 16-for-100 reverse stock split, with the stock price rising by 40.72%. Industry policy changes are driving research into psychedelic drugs. Theriva Biologics is up 70.61% in pre-market trading. Based on recent key news: On April 17, Theriva Biologics announced it will present additional data from its VIRAGE Phase 2B clinical trial at the AACR 2026 annual meeting. The trial targets metastatic pancreatic cancer and demonstrates the efficacy of VCN-01, driving the stock price up. On April 17, the company plans to conduct a low-dose study to test whether more frequent and prolonged VCN-01 administration can further improve outcomes. This news has bolstered market confidence in its therapeutic effects, further pushing up the stock price On April 20th, Theriva Biologics announced poster data on the combination treatment of VCN-01 with gemcitabine/nab-paclitaxel, showing improvements in overall survival and progression-free survival. This data further confirms the potential of VCN-01, leading to a significant increase in stock price. The clinical trial data is positive, and the market response is strong. Clearmind Medicine rose 54.25% in pre-market trading, based on recent key news: On April 19th, U.S. President Trump signed an executive order to accelerate the research and approval process for psychedelic therapies. This move aims to help veterans suffering from severe mental illnesses by providing new treatment options. Clearmind Medicine has gained market attention due to its research in the field of psychedelic drugs, resulting in a substantial increase in stock price. The policy on psychedelic drug research is favorable